Keros at a Crossroads: Pivots, Pipelines, and Investor Scrutiny

LEXINGTON, MA – February 18, 2026 – Keros Therapeutics is set to step into the investor spotlight, with President and CEO Jasbir S. Seehra, Ph.D., scheduled to present at three major healthcare conferences over the next month. The presentations, beginning with the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, come at a critical juncture for the clinical-stage biopharmaceutical company, which has undergone a dramatic strategic transformation over the past year.

Investors and analysts will be listening intently as Keros (Nasdaq: KROS) outlines its path forward following a significant pipeline shake-up, a lucrative licensing deal, and a major capital return to shareholders. The company’s appearances at the Oppenheimer, TD Cowen, and Leerink Partners conferences represent a crucial opportunity to articulate its refocused vision and build confidence in its streamlined clinical strategy.

A Year of Strategic Shifts and Financial Fortification

The past year has been one of profound change for Keros. In May 2025, the company made the difficult decision to completely discontinue its cibotercept program for pulmonary arterial hypertension (PAH). The move followed the observation of serious adverse events—specifically, fluid buildup around the heart—and a lack of compelling efficacy in a Phase 2 study. This setback led to a painful but necessary restructuring, resulting in a 45% reduction of the company’s workforce and a strategic pivot to concentrate its resources elsewhere.

That pivot has been decisively toward its neuromuscular disease program. However, the company’s financial footing was dramatically strengthened not by its new focus, but by its most advanced asset. In a landmark deal announced in December 2024, Keros entered into an exclusive licensing agreement with Takeda Pharmaceuticals for the global rights to elritercept (KER-050). The agreement, which became effective in January 2025, provided Keros with a non-dilutive upfront payment of $200 million, significantly bolstering its balance sheet.

Flush with cash, Keros announced a plan in October 2025 to return $375 million in excess capital to its stockholders through measures including share repurchases. This series of events—a clinical failure, a strategic refocus, a major partnership, and a substantial capital return—has reshaped the company’s narrative. The upcoming conference presentations will be the first major platform for leadership to detail how these pieces fit together into a cohesive and value-creating strategy for the future.

Spotlight on the Pipeline: Elritercept and Rinvatercept

With the cibotercept program in the rearview mirror, Keros's future now rests on two key assets targeting disorders linked to dysfunctional transforming growth factor-beta (TGF-ß) protein signaling. The company's ability to execute on the clinical development of these candidates will be the ultimate measure of its recent pivot.

Elritercept (KER-050), the subject of the Takeda deal, remains the company’s most advanced candidate. It is being developed to treat cytopenias—low blood cell counts—in patients with myelodysplastic syndromes (MDS) and myelofibrosis (MF). Data presented in late 2024 from an ongoing Phase 2 trial in lower-risk MDS was highly encouraging, showing that elritercept could produce durable transfusion independence, with a median response duration exceeding 134 weeks. Critically, these clinical benefits were paired with patient-reported improvements in fatigue. The drug, which has received Fast Track designation from the FDA for this indication, is now advancing toward a global Phase 3 study, dubbed the RENEW trial.

While Takeda will now spearhead much of elritercept’s global development, Keros has declared it is “going all in” on its other key asset, rinvatercept (KER-065). Now positioned as the company’s lead internal program, rinvatercept is being developed for severe neuromuscular conditions, including Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS), with potential future applications in obesity. Following robust preclinical and Phase 1 data, Keros is poised to launch a pivotal Phase 2 study for rinvatercept in DMD during the first quarter of 2026, pending final regulatory feedback. Success with rinvatercept is central to validating the company’s new, more focused R&D strategy.

Navigating Investor Expectations and Market Headwinds

The timing of the conference circuit is particularly significant. Keros is scheduled to report its fourth-quarter and full-year 2025 financial results on February 25, the same day as its presentation at the Oppenheimer conference. Investors will be scrutinizing the report for updates on the company’s cash runway, which was projected to last into 2028, and for further details on the execution of the Takeda partnership and the capital return program.

Market sentiment surrounding Keros remains mixed, reflecting both the promise of its pipeline and the risks inherent in clinical-stage biotech. The consensus analyst rating is currently a “Hold,” yet the average 12-month price target of $22.29 suggests a potential upside of nearly 38% from its current trading price of around $16.52. Analysts at Oppenheimer maintain an “Outperform” rating with a $27.00 price target, citing the potential of the upcoming rinvatercept trial as a key value driver.

Investors will be looking for clear updates on clinical trial enrollment for elritercept's Phase 3 and a definitive timeline for the initiation of rinvatercept's Phase 2. They will also be keen to understand the competitive landscape, particularly for elritercept in the crowded MDS market, where it will need to differentiate itself from established therapies and a growing number of novel agents.

The Science of Signaling: Keros's Bet on TGF-ß

Underpinning Keros’s entire strategy is its deep expertise in the TGF-ß family of proteins, which act as master regulators of tissue growth, repair, and maintenance throughout the body. The TGF-ß signaling pathway is notoriously complex, capable of both promoting and inhibiting cellular processes, which has made it a challenging but highly attractive therapeutic target.

Keros has positioned itself as a leader in deciphering this complexity. Its therapeutic candidates, like elritercept, are engineered as “ligand traps”—specialized proteins designed to selectively bind to and inhibit overactive signaling proteins within the TGF-ß family. In the case of elritercept, the targets are activin A and other ligands known to suppress the production of healthy red blood cells and platelets, leading to anemia and thrombocytopenia in diseases like MDS.

By precisely modulating this pathway, Keros aims to develop potentially disease-modifying treatments rather than simply managing symptoms. The upcoming presentations will provide a platform for Dr. Seehra to reinforce this scientific foundation and connect it directly to the clinical milestones that the company believes will unlock significant value for both patients and shareholders. The challenge will be to convince a cautious market that its focused bet on this intricate biology is the right one.